Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170962 · ClinicalTrials.gov registry record · Phase 2
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
A Phase 2 study of Hepatitis C Virus, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 512
- Enrollment target
- 20
- Study locations
NCT01170962 is a Phase 2 study of Hepatitis C Virus that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 512 participants, above the 147-participant average among 3 other Hepatitis C Virus trials with a reported enrollment target (248% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT01170962, a Phase 2 study of Hepatitis C Virus, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 512 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-790052
- DRUG peginterferon alfa-2a
- DRUG ribavirin
Study Locations (20)
California
- Scripps Clinic - La Jolla
- CLI - Los Angeles
- Desta Digestive Disease Medical Center - San Diego
- University Of California At San Francisco - San Francisco
- California Pacific Medical Center - San Francisco
- Kaiser Permanente Medical Center - San Francisco
Maryland
- Mercy Medical Center - Baltimore
- Digestive Disease Associates, P.A. - Baltimore
- Johns Hopkins Medical Institutions - Lutherville
Florida
- University Of Florida Hepatology - Gainesville
- Miami Research Associates - South Miami
New York
- Samuel S. Stratton Vamc - Albany
- James Sungsik Park, M.D. C.N.S.C. - Great Neck
Alabama
- Alabama Liver & Digestive Specialists (Alds) - Montgomery
Colorado
- Transplant Center And Hepatology Clinic, B-154 - Aurora
Connecticut
- Yale University School Of Medicine - New Haven
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01170962
The ClinicalTrials.gov registry entry for NCT01170962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 147-participant average among 3 other Hepatitis C Virus trials with a reported enrollment target (248% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C Virus appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01170962 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Maryland, Florida.
Frequently Asked Questions
What is clinical trial NCT01170962 about?
NCT01170962 is a clinical study titled "Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment". The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.
What is the current status of trial NCT01170962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 512 participants. The study started on 2010-08. Estimated completion is 2012-12.
What conditions does trial NCT01170962 study?
This clinical trial studies the following conditions: Hepatitis C Virus.
What interventions are being tested in trial NCT01170962?
The interventions under investigation include: Placebo (DRUG), BMS-790052 (DRUG), peginterferon alfa-2a (DRUG), ribavirin (DRUG).
Who is sponsoring clinical trial NCT01170962?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01170962 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
COMPLETED · Phase 2
-
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
RECRUITING · NA
-
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.